Company Overview
Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.
Recent News
Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia
Propanc Biopharma’s Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030
Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads
Stock Overview
09/28/2023 03:03 PM EDT
Investor Relations
Propanc Biopharma, Inc.
T: +61-03-9882-6723
irteam@propanc.com